Abstract The use of established fluoroquinolones, such as ciprofloxacin and ofloxacin, as empirical therapy for the treatment of moderate-to-severe respiratory tract infections is limited by their poor activity against gram-positive and atypical pathogens. Data from in vitro susceptibility studies and in vivo animal protection models suggest that the new fluoroquinolone, trovafloxacin, compared with ciprofloxacin and ofloxacin offers equivalent activity against gram-negative pathogens and improved activity against gram-positive pathogens. In particular, susceptibility data indicate that trovafloxacin is at least 16-fold more potent than either ciprofloxacin or ofloxacin against penicillin-susceptible and penicillin-resistant strains of Streptococcus pneurnoniae. Other susceptible pathogens include Streptococcus pyogenes, vancomycin-susceptible Enterococcus faecalis and the atypical respiratory pathogens Legionella pneurnophila, Mycoplasma pneumoniae and Chlamydia pneumoniae. In vivo studies involving models of protection against acute systemic infection and pneumococcal pneumonia in mice, and Legionnaires' disease in guinea pigs, indicate that the antibacterial spectrum observed for trovafloxacin in vitro extends to the in vivo setting. Together, these findings suggest that trovafloxacin may offer clinical efficacy against respiratory pathogens superior to that of ciprofloxacin and of ofloxacin, and may find a useful role as empiric therapy in both the community and hospital setting.
Introduction
High incidences of penicillin resistance [1] , escalating /3-1actamase production and poor activity against atypical pathogens are increasingly limiting the use of /3-1actam antibiotics for the empiric treatment of respiratory tract infections. Macrolides have been used as alternative agents, but there is growing concern about the emergence of resistance to this class of antibiotics, particularly with Streptococcus pneumoniae. Clinicians are now searching for other antibiotics that can provide cost-effective, ideally single-agent, empiric therapy for moderate-to-severe community-and hospital-acquired respiratory infections.
The established fluoroquinolone antibiotics exhibit excellent activity against a broad spectrum of gramnegative pathogens, resulting in their use as monotherapy for acute exacerbations of chronic bronchitis and as part of a combination therapy for hospitalacquired pneumonia. By contrast, the activity of established fluoroquinolones is only moderate against Streptococcus pneumoniae and Mycoplasrna pneumoniae; thus their use as first-line therapy for communityacquired pneumonia is not widely accepted.
There is a need, therefore, for new fluoroquinolones that offer improved activity against gram-positive and atypical respiratory pathogens. Trovafloxacin is a novel fluoronaphthyridone with a similar structure to existing fluoroquinolones. This article reviews the preclinical evaluation of trovafloxacin against respiratory pathogens that are isolated from widely diverse geographical locations.
Chemical Structure
Most currently available quinolone antibacterial agents possess the same core structure (Figure la) . Experience gained during the development of the quinolones has confirmed the importance of the nitrogen at N-l, the ketone at C-4, the carboxylic group at C-3 and the fluoride at C-6 for potent antimicrobial activity. Most of the variation in structure and activity within this family of compounds is derived from substitutions at positions N-1 and C-7 [2] . Trovafloxacin (CP-99,219), a fluoronaphthyridone, while retaining the quinolone core structure, has a combination of structural moieties not found in other fluoroquinolones: a 3-azabicyclo[3.1.0]hexyl substitution at C-7 and a 2,4-difluorophenyl group at the N-1 position (Figure lb) . The nitrogen atom at the C-8 position, which renders trovafloxacin a naphthyridone, appears to be associated with a long elimination half-life [3] .
Mode of Action of Trovafloxacin
Trovafloxacin, in common with the established fluoroquinolones, elicits its bactericidal action by interacting with and inhibiting the action of bacterial DNA gyrase, i.e., topoisomerase II [4, 5] . A second topoisomerase, topoisomerase IV, appears to be a secondary target for fluoroquinolones in Escherichia coli [6] and Neisseria gonorrhoeae [7] , and the primary target for ciprofloxacin and trovafloxacin in Staphylococcus aureus [8] Streptococcus pneumoniae [9] . The agent does not inhibit eukaryotic topoisomerase II and, therefore, is not cytotoxic towards human cells [10] .
Mechanisms of Resistance to Fluoroquinolones
The dominant factor in the emergence of resistance to fluoroquinolones appears to be mutation of DNA gyrase in gram-negative and of topoisomerase IV in gram-positive organisms [3] . An additional mechanism of resistance includes the presence of efflux transporters [11] [12] [13] , which actively export ftuoroquinolones from within the bacteria. The role of porins and outer membrane permeability is more questionable.
Studies in Streptococcus pneumoniae [9] , Staphylococcus aureus [14] and Pseudomonas aeruginosa [15] have indicated that trovafloxacin has a reduced potential to select fluoroquinolone resistance compared with other agents, such as ciprofloxacin. Enterococcus faecium [39, 40] .
Antimicrobial Activity in Vitro
Gram-Negative Respiratory Pathogens. Overall, trovafloxacin is as active in vitro as ciprofloxacin and more so than ofloxacin against these pathogens ( Against most of the other gram-negative respiratory pathogens tested, trovafloxacin offers an activity gener-(MIC _.0.5 nag/I); pen-S, penicillin-susceptible (MIC < 0.5 rag/t); van-S, vancomycin-susceptible ally between that of ciprofloxacin and ofloxacin. Overall, the data indicate that the activity of trovafloxacin is comparable to the activities of ciprofloxacin and ofloxacin across a broad spectrum of gram-negative pathogens.
Atypical Respiratory Pathogens. The median MIC9os
derived from in vitro susceptibility studies indicate that trovafloxacin is as active as ofloxacin against Chlamydia pneumoniae and is more active against Legionella pneumophila and Mycoplasrna pneumoniae (Table   3) . In vitro studies also show that trovafloxacin is more active than ciprofloxacin against Legionella pneumophila and Mycoplasma pneumoniae.
Animal Models of Infection
In an acute systemic infection model, mice were infected with one of a range of gram-positive and gramnegative organisms administered via intraperitoneal injection [45] . Each treatment group of ten mice received an oral dose of antibiotic administered 0.5 and 4 h after infection. The numbers of mice that survived until day 4 were determined and used to calculate the protective dose for 50% of the animals (PDs0).
Gram-Positive Respirator>" Pathogens.
Trovafloxacin provided effective treatment in the acute systemic infection model [44] and was generally superior to ciprofloxacin or ofloxacin ( Table 4 ). The PDs0 values indicate that trovafloxacin was particularly effective against two strains of Streptococcus pneumoniae, whereas both ciprofloxacin and ofloxacin proved ineffective even at the highest dose employed (50 mg/kg/ day).
Against a methicillin-resistant Staphylococcus aureus strain (01A0129), trovafloxacin and ciprofloxacin appeared to be equally effective. However, data for other Staphylococcus aureus strains highlight clear differences in potency among the fluoroquinolones. Trovafloxacin was more than fourfold more effective than ciprofloxacin against a methicillin-susceptible strain (01A0400) and was the only fluoroquinolone to demonstrate activity against one of the fluoroquinolone-resistant (trovafloxacin MIC=3.12mg/1) strains (01A1080). None of the fluoroquinolones exhibited in vivo activity against strain 01A1063, which is highly resistant to fluoroquinolones (trovafloxacin MIC= 25 mg/1).
The pattern of superior activity for trovafloxacin extends to the other pathogens investigated. Trovafloxacin was nearly threefold more active than ciprofloxacin in protecting mice against Streptococcus pyogenes infection and was effective against Enterococcus faecalis, against which both ciprofloxacin and ofloxacin proved ineffective at the highest dose tested. In these tests, the efficacy observed with trovafloxacin generally paralleled its in vitro potency against the infecting pathogen.
Two additional animal protection studies have demonstrated the relative activities of trovafloxacin, ciprofloxacin and ofloxacin in treating infections caused by Streptococcus pneumoniae. In one study, two groups of ten mice were infected intranasally with Streptococcus pneumoniae strain Pocidalo 4241 [47] . Oral twice-daily therapy with trovafloxacin or ciprofloxacin was initiated 18 h after infection and maintained for 3 days. Survivors were monitored over 10 days, after which the PDso was calculated. The results suggest that trovafloxacin is more potent in vivo than ciprofloxacin. Trovafloxacin protected 90-100% of the animals with oral therapies of 12.5-50 mg/kg, giving a PDso of 2.1 mg/kg. In contrast, ciprofloxacin protected only 20-30% of challenged animals at doses of 75-100 mg/kg.
A second study employed a similar mouse pneumonia model to compare the activities of trovafloxacin, ciprofloxacin and ofloxacin against one penicillin-susceptible Streptococcus pneumoniae strain (Pocidalo 4241) in immunocompetent mice and three penicillin-resistant isolates in leucopenic mice [48] . Therapy began 6 h and 3 h, respectively, after infection and involved the administration of two subcutaneous doses per day for 3 days. Untreated, control mice died by day 3 post-challenge in this model. Survival rates with trovafloxacin were significantly greater than with ciprofloxacin or ofloxacin. A once-daily 25 mg/kg dose of trovafloxacin protected 91% of the mice infected with the penicillinsusceptible strain 4241 and 66-100% of mice infected with penicillin-resistant strains. By comparison, in the case of ciprofloxacin, the next most effective agent, a dose of 100mg/kg protected only 23% and 58% of mice, respectively.
An indication of the greater clinical potential of trovafloxacin against Streptococcus pneumoniae is also provided by its superior distribution into the lung tissues compared with ciprofloxacin. Girard et al. [46] found that, in mice infected with strain 4241, the maximum concentration of trovafloxacin in lung tissue was at least twice that of ciprofloxacin, and that the half-life of trovafloxacin was over threefold greater. Consequently, the area under the lung concentration-time curve for trovafloxacin was nearly sixfold greater than for ciprofloxacin. [46] . Trovafloxacin was slightly more active against Enterobacter cloacae and Klebsiella pneurnoniae than ciprofloxacin, but slightly less so than ciprofloxacin and ofloxacin against Escherichia coli and Pseudomonas aeruginosa, and markedly less effective than ciprofloxacin against Morganella morganii ( Table 5 ).
The activity of trovafloxacin against Proteus rnirabilis was slightly higher than that of ciprofloxacin and markedly higher than that of ofloxacin.
Atypical Respiratory Pathogens. The in vivo activity of trovafloxacin against Legionella pneumophila has been explored and compared with that of ofloxacin in an animal model featuring lethal lung infections with this atypical pathogen [44] . Guinea pigs infected intratracheally with Legionella pneumophila serogroup 1 strain F889 received a single dose of trovafloxacin (7.5 rag/ kg), ofloxacin (10 mg/kg) or saline, administered intraperitoneally once daily for 5 days.
All guinea pigs treated with trovafloxacin or ofloxacin survived 14 days after infection, whereas none of the control guinea pigs survived more than 5 days. No significant differences in lung histology were noted between the trovafloxacin-and ofloxacin-treated animals who survived. Only two of the seven lung samples from the trovafloxacin treatment group were positive for Legionella pneumophila, compared with three of the seven lung samples from the ofloxacin group. The major difference observed between the treatment groups was slower weight gain in the trovafloxacin group, which could have been attributable to lower initial weights in this group before infection [44] .
A similar study involving the same experimental model has shown that trovafloxacin (5 mg/kg/day) completely eradicated Legionella pneumophila from the lungs and spleen in all animals after 4-5 days of treatment and that Legionella could not be recovered after 28 days (E. Millas et al., 36th ICAAC, 1996, Abstract no. E76).
The in vitro susceptibility data, combined with better in vivo activity than either ciprofloxacin or ofloxacin, led Edelstein et al. [44] to conclude that trovafloxacin is one of the most active antimicrobial agents tested against Legionella species, being more effective than ciprofloxacin and other antibiotics such as azithromycin, erythomycin, clavulanic acid and tazobactam.
Tissue and Intracellular Penetration of Trovafloxacin
Positron emission tomography performed in healthy volunteers revealed that the peak concentration of trovafloxacin in lung following a 200 mg dose was 22. [44] showed that the maximum concentration of trovafloxacin in guinea pig alveolar macrophages in vitro was 28-fold greater than the concentration in extracellular fluid. Concentration in serum, alveolar macrophages, epithelial lining and bronchial mucosa of 1.01mg/kg, 0.37, 10.23 and 0.93 mg/1, respectively, have been recorded 24 h after a single oral dose of 200 mg trovafloxacin in humans [47] . These concentrations exceeded even the highest median MIC90 values of respiratory pathogens presented in Tables 1-3 , and should be sufficiently high to ensure bacterial eradication.
Conclusions
Fluoroquinolones comprise just one of many classes of antimicrobial agents used to treat the gamut of community-and hospital-acquired respiratory tract infections in humans. Although ciprofloxacin and ofloxacin find some use in the treatment of acute exacerbations of chronic bronchitis and in combination with other agents, for hospital-acquired pneumonia, their more widespread use for community-acquired pneumonia is limited by their relatively poor activity against pneumococci and atypical pathogens. Further, the use of pres-ently marketed fluoroquinolones has been accompanied by the emergence of fluoroquinolone-resistant Staphylococcus aureus and Streptococcus pneumoniae strains. Therefore, a demand exists for new antibiotics with broad-spectrum activities that enable them to be prescribed with confidence for empiric monotherapy.
The resuks of in vitro and in vivo studies indicate that trovafloxacin offers activity comparable to that of ciprofloxacin and ofloxacin against gram-negative respiratory pathogens together with superior activity against gram-positive organisms. Trovafloxacin is also active against the atypical respiratory pathogens. Its extensive activity against pathogens commonly implicated in respiratory infections, together with its ability to achieve concentrations in respiratory tissue far in excess of MICs, suggests that trovafloxacin may provide effective empiric treatment of community-and hospital-acquired infections, including sinusitis, acute exacerbations of chronic bronchitis, community-and hospital-acquired pneumonia, and atypical pneumonia.
